GlassScriptPhysician profile
Eman M Sharawy
NPI 1902998032
$9,028.04
in general payments reported to CMS, 2019-2025
23 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $631 · 2021: $1,177 · 2022: $1,094 · 2023: $1,589 · 2024: $1,965 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.81 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,690.50 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,447.89 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $1,300.74 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $874.26 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $809.49 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $614.62 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $433.37 | 2019-2022 | |
| Alkermes, INC. | $393.14 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $270.14 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $213.15 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $180.55 | 2019-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $171.68 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $163.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.76 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $55.59 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $43.76 | 2025 | Dyanavel Xr |
| Allergan, INC. | $42.67 | 2020 | |
| Shire North American Group INC | $42.16 | 2019 | |
| Avanir Pharmaceuticals, INC. | $40.46 | 2020-2021 | |
| Axsome Therapeutics, INC. | $36.75 | 2023-2024 | Auvelity |
| Celgene Corporation | $32.94 | 2025 | Cobenfy |
| Indivior INC. | $27.21 | 2021-2024 | Perseris |
| Corium, LLC | $21.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Sharawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.